| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 47 Number 5
Volume 47 Number 4
Volume 47S Number 1
Volume 47 Number 3
Volume 47 Number 2
Volume 47 Number 1
Earlier issues
Volume 47 Number 4 Volume 47 Number 5

previous article next article

Research articles

ScienceAsia 47 (2021): 578-584 |doi: 10.2306/scienceasia1513-1874.2021.078

Hepatic miR-122 expression correlated with IL-28B genetic polymorphisms in hepatocellular carcinoma patients with living donor liver transplantation

Chih-Chi Wanga,b,c, Kuang-Tzu Huangc,d, Kuang-Den Chenc,d, Li-Wen Hsuc, Chih-Che Lina,b,c, King-Wah Chiub,c,e,*

ABSTRACT:     Hepatocellular carcinoma (HCC) recurrence after living donor liver transplantation (LDLT) remains problematic. The genetic and molecular characteristics of patients may affect HCC recurrence. We evaluated the effects of microRNA-122 (miR-122) and interleukin-28B (IL-28B) genetic polymorphisms on patients with HCC following LDLT in 60 patients. MiR-122 and IL-28B polymorphisms were evaluated in plasma and liver tissues after LDLT. HBV, HCV, dual HBV/HCV infection, and non-B non-C were detected in 26, 22, 3, and 9 patients, respectively, over a median follow-up time of 20.5 (1033) months. miR-122 was significantly higher in the liver than in the plasma of patients with HBV, HCV, dual HBV/HCV, and non-B non-C. Hepatic miR-122 expression was significantly higher for genotype TT and genotype TT plus GT (p = 0.005) compared with genotype GG of IL-28B rs8099917 and significantly higher in > 6% fatty liver than in < 5% or no fatty liver. In conclusion, high hepatic miR-122 was correlated with the IL-28B rs8099917 genotypes TT and GT and with > 6% fatty liver and, thus, may play a major role in HCC.

Download PDF

25 Downloads 60 Views

a Division of General Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
b Chang Gung University, College of Medicine, Taoyuan, Taiwan
c Liver Transplantation Center, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
d Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
e Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

* Corresponding author, E-mail: c471026@ms6.hinet.net

Received 2 Oct 2020, Accepted 25 Apr 2021